Skip to main content

Published locations for Dose escalation of biosimilar infliximab for RA patients deemed cost effective, to a point

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Dose escalation of biosimilar infliximab for RA patients deemed cost effective, to a point

User login

  • Reset your password
  • /content/dose-escalation-biosimilar-infliximab-ra-patients-deemed-cost-effective-point
  • /internalmedicinenews/article/214655/rheumatoid-arthritis/dose-escalation-biosimilar-infliximab-ra
  • /rheumatologynews/article/214655/rheumatoid-arthritis/dose-escalation-biosimilar-infliximab-ra
  • /rheumatology/article/214655/rheumatoid-arthritis/dose-escalation-biosimilar-infliximab-ra-patients
  • /internalmedicine/article/214655/rheumatoid-arthritis/dose-escalation-biosimilar-infliximab-ra
  • /emergencymedicine/article/214655/rheumatoid-arthritis/dose-escalation-biosimilar-infliximab-ra